Literature DB >> 16979943

Preferential silencing of a common dominant rhodopsin mutation does not inhibit retinal degeneration in a transgenic model.

Alessandra Tessitore1, Fabiana Parisi, Michela Alessandra Denti, Mariacarmela Allocca, Umberto Di Vicino, Luciano Domenici, Irene Bozzoni, Alberto Auricchio.   

Abstract

Autosomal dominant retinitis pigmentosa caused by the frequent rhodopsin P23H mutation is characterized by progressive photoreceptor cell death eventually leading to blindness and for which no therapies are available. Considering the gain-of-function effect exerted by the P23H mutation, strategies aimed at silencing the expression of the mutated allele, like RNA interference, are desirable. We have designed small interfering RNAs (siRNA) to silence specifically the P23H rhodopsin allele expressed by a transgenic rat model of the disease. We have selected in vitro one siRNA and generated an adeno-associated viral (AAV) vector expressing the short hairpin RNA (shRNA) based on the selected siRNA. In vitro the shRNA significantly inhibits the expression of the P23H but not the wild-type rhodopsin allele. Subretinal administration of the AAV2/5 vector encoding the shRNA in P23H transgenic rats results in inhibition of rhodopsin P23H expression that is not able to prevent or block photoreceptor degeneration. Since rhodopsin is the most abundant rod photoreceptor protein, systems resulting in more robust shRNA expression in the retina may be required to achieve therapeutic efficacy in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16979943     DOI: 10.1016/j.ymthe.2006.07.008

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  18 in total

1.  Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy.

Authors:  Naomi Chadderton; Sophia Millington-Ward; Arpad Palfi; Mary O'Reilly; Gearóid Tuohy; Marian M Humphries; Tiansen Li; Peter Humphries; Paul F Kenna; G Jane Farrar
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

Review 2.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

3.  Mutation-independent rescue of a novel mouse model of Retinitis Pigmentosa.

Authors:  D L Greenwald; S M Cashman; R Kumar-Singh
Journal:  Gene Ther       Date:  2012-07-19       Impact factor: 5.250

Review 4.  Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.

Authors:  Pasqualina Colella; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2012-08       Impact factor: 5.695

5.  Phenotypic characterization of P23H and S334ter rhodopsin transgenic rat models of inherited retinal degeneration.

Authors:  Matthew M LaVail; Shimpei Nishikawa; Roy H Steinberg; Muna I Naash; Jacque L Duncan; Nikolaus Trautmann; Michael T Matthes; Douglas Yasumura; Cathy Lau-Villacorta; Jeannie Chen; Ward M Peterson; Haidong Yang; John G Flannery
Journal:  Exp Eye Res       Date:  2017-11-06       Impact factor: 3.467

6.  AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa.

Authors:  Haoyu Mao; Thomas James; Alison Schwein; Arseniy E Shabashvili; William W Hauswirth; Marina S Gorbatyuk; Alfred S Lewin
Journal:  Hum Gene Ther       Date:  2011-03-07       Impact factor: 5.695

7.  Gene delivery of wild-type rhodopsin rescues retinal function in an autosomal dominant retinitis pigmentosa mouse model.

Authors:  Haoyu Mao; Marina S Gorbatyuk; William W Hauswirth; Alfred S Lewin
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

8.  Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector.

Authors:  Artur V Cideciyan; Raghavi Sudharsan; Valérie L Dufour; Michael T Massengill; Simone Iwabe; Malgorzata Swider; Brianna Lisi; Alexander Sumaroka; Luis Felipe Marinho; Tatyana Appelbaum; Brian Rossmiller; William W Hauswirth; Samuel G Jacobson; Alfred S Lewin; Gustavo D Aguirre; William A Beltran
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-20       Impact factor: 11.205

9.  Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery.

Authors:  M Gorbatyuk; V Justilien; J Liu; W W Hauswirth; A S Lewin
Journal:  Vision Res       Date:  2007-02-12       Impact factor: 1.886

Review 10.  Progress in Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa.

Authors:  Raghavi Sudharsan; William A Beltran
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.